RecruitingNCT05454787
Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)
Sponsor
AstraZeneca
Enrollment
300 participants
Start Date
Jun 2, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions.
Eligibility
Inclusion Criteria1
- All patients treated with this drug to neutralize the anticoagulant effect of a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) at onset of a life-threatening bleeding episode or a unarrestable bleeding episode.
Exclusion Criteria1
- N/A
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(72)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05454787